Gujarat Themis Biosyn Ltd
Gujarat Themis Biosyn Q2 FY26 investor presentation: Revenue & Margins
Q2 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Gujarat Themis Biosyn Ltd's Q2 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentationreports, not management guidance.
The short version
Revenue for Q2 FY26: Rs. EBITDA for Q2 FY26: Rs.
From Gujarat Themis Biosyn Ltd's Q2 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Revenue for Q2 FY26: Rs. 42.35 crore, up 21.98% year-on-year from Rs. 34.72 crore in Q2 FY25 (Page 6).
- Income from Operations in Q2 FY26: Rs. 42.35 crore, a 35.87% increase compared to Q2 FY25 (Page 6).
- Management comment states Q2 FY26 top line grew 22% year-on-year to Rs. 42.3 crore (Page 4).
- Improvement attributed to higher production and sales volumes vis-à-vis previous corresponding quarter (Page 4).
- EPS for Q2 FY26 is Rs. 1.31 compared to Rs. 0.97 in Q2 FY25, a 35.05% increase (Page 6).
- Outlook: Expansion of fermentation block completed in October 2025 doubling capacity to 990 KL, boosting manufacturing capability (Page 4).
- API facility operational with validation in progress; forward integration into fermentation-based and synthetic APIs aimed at export markets (Page 4).
2 more points from Gujarat Themis Biosyn Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Gujarat Themis Biosyn Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Completed expansion of new fermentation block in October 2025, doubling total capacity to 990 KL; commercial production of Rifa-S and Rifa-O began in new unit (Page 4).
- API facility operational with validation batches in progress, as part of forward integration into fermentation-based and synthetic APIs targeting export markets (Page 4).
- Ongoing Capex plan includes new product development, commissioning of R&D unit to international standards, brewing new intermediate molecules (Page 13).
- Focus on expanding fermentation capacity for new products aimed at domestic and export markets (Page 13).
- New infrastructure development to comply with strictest regulatory authorities, enhancing fermentation capacities (Page 15).
2 more points from Gujarat Themis Biosyn Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Gujarat Themis Biosyn Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Gujarat Themis Biosyn Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹44 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Gujarat Themis Biosyn Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Wanbury Ltd (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Senores Pharmaceuticals Ltd (Q2 FY26)
Earnings (PAT) growth has been very strong recently (e.g., 131% Y-o-Y growth in Q2) with sustained profitability momentum. Key concall takeaways from Senores…
- Caplin Point Laboratories Ltd (Q2 FY26)
After 2 years, operating margins could improve to around 40%, if markets remain favorable. Key concall takeaways from Caplin Point Laboratories Ltd's Q2 FY26…
- Indoco Remedies Ltd (Q2 FY26)
R&D spend will reduce from ~5% to ~4% of sales, focusing on vertically integrated, higher efficiency products. Key concall takeaways from Indoco Remedies Ltd's…
Arthneeti Pro · Annual
Gujarat Themis Biosyn Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Gujarat Themis Biosyn Ltd Q2 FY26 results?
Revenue for Q2 FY26: Rs. EBITDA for Q2 FY26: Rs.
What is Gujarat Themis Biosyn Ltd share price analysis?
Gujarat Themis Biosyn Ltd currently shows a neutral. The stock trades at a P/E of 99.8 with a market cap of ₹4,861 Cr. Investors should review the full earnings analysis for detailed insights.
Is Gujarat Themis Biosyn Ltd planning capital expenditure?
Completed expansion of new fermentation block in October 2025, doubling total capacity to 990 KL; commercial production of Rifa-S and Rifa-O began in new unit (Page 4).
Keep Gujarat Themis Biosyn Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.